Literature DB >> 7354807

The enzymatic defect in variegate prophyria. Studies with human cultured skin fibroblasts.

D A Brenner, J R Bloomer.   

Abstract

Fecal protoporphyrin is increased in patients with variegate porphyria, even during clinical remission, suggesting an enzymatic defect in the terminal portion of the heme biosynthetic pathway. We measured the activities of protoporphyrinogen oxidase, which catalyzes the oxidation of protoporphyrinogen to protoporphyrin, and heme synthase, which catalyzes the chelation of iron to protoporphyrins, in cultured skin fibroblasts from five normal controls and five patients with variegate porphyria. Heme synthase activity was shown to be normal in variegate porphyria cells by direct assay in cell sonicates and indirect assay in intact cells. Protoporphyrinogen oxidase activity, however, was reduced to 43 per cent of normal in sonicates of variegate porphyria cells (0.90 +/- 0.13 vs. 2.12 +/- 0.25 nmol of protoporphyrin per milligram of protein per hour [mean +/- S.E.M.] [P less than 0.005]). We conclude that protoporphyrinogen oxidase activity is deficient in variegate porphyria. Fecal protoporphyrin may increase because an excess amount of protoporphyrinogen is excreted into bile and subsequently auto-oxidized to protoporphyrin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7354807     DOI: 10.1056/NEJM198004033021401

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Functional Characterization of Five Protoporphyrinogen oxidase Missense Mutations Found in Argentinean Variegate Porphyria Patients.

Authors:  Manuel Méndez; Barbara X Granata; María J Morán Jiménez; Victoria E Parera; Alcira Batlle; Rafael Enríquez de Salamanca; María V Rossetti
Journal:  JIMD Rep       Date:  2011-12-06

2.  Chester porphyria: a clinical study of a new form of acute porphyria.

Authors:  M R Qadiri; S E Church; K E McColl; M R Moore; G R Youngs
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

3.  Protoporphyrinogen oxidation, a step in heme synthesis in soybean root nodules and free-living rhizobia.

Authors:  N J Jacobs; S E Borotz; M L Guerinot
Journal:  J Bacteriol       Date:  1989-01       Impact factor: 3.490

4.  Crystal structure of protoporphyrinogen oxidase from Myxococcus xanthus and its complex with the inhibitor acifluorfen.

Authors:  Hazel R Corradi; Anne V Corrigall; Ester Boix; C Gopi Mohan; Edward D Sturrock; Peter N Meissner; K Ravi Acharya
Journal:  J Biol Chem       Date:  2006-10-17       Impact factor: 5.157

5.  Human protoporphyrinogen oxidase: expression, purification, and characterization of the cloned enzyme.

Authors:  T A Dailey; H A Dailey
Journal:  Protein Sci       Date:  1996-01       Impact factor: 6.725

6.  Linkage between the variegate porphyria (VP) and the alpha-1-antitrypsin (PI) genes on human chromosome 14.

Authors:  S Bissbort; H W Hitzeroth; D P du Wentzel; C W Van den Berg; H Senff; T F Wienker; K Bender
Journal:  Hum Genet       Date:  1988-07       Impact factor: 4.132

7.  Oxidation of protoporphyrinogen to protoporphyrin, a step in chlorophyll and haem biosynthesis. Purification and partial characterization of the enzyme from barley organelles.

Authors:  J M Jacobs; N J Jacobs
Journal:  Biochem J       Date:  1987-05-15       Impact factor: 3.857

8.  Homozygous variegate porphyria: two similar cases in unrelated families.

Authors:  G M Murphy; J L Hawk; I A Magnus; D F Barrett; G H Elder; S G Smith
Journal:  J R Soc Med       Date:  1986-06       Impact factor: 5.344

9.  Effect of rifampicin on haem and bilirubin metabolism in man.

Authors:  K E McColl; G G Thompson; E el Omar; M R Moore; B K Park; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

10.  Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria.

Authors:  P Meissner; P Adams; R Kirsch
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.